Imatinib

Major

Imatinib Acetaminophen And Codeine Capital® & Codeine Explained Increased acetaminophen levels Details Imatinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Imatinib Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Imatinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Imatinib Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Imatinib Acetaminophen Acephen Increased acetaminophen levels Details Imatinib Acetaminophen Injection Acephen Increased acetaminophen levels Details Imatinib Acetaminophen Rectal Acephen Increased acetaminophen levels Details Imatinib Apixaban Eliquis Explained Increased apixaban exposure Details Imatinib Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Imatinib Azathioprine Azasan An increased risk of hepatotoxicity Details Imatinib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Imatinib Amlodipine Amvaz® Increased amLODIPine exposure, an increased risk of hypotension and edema and increased risk of imatinib toxicity Details Imatinib Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Bedaquiline Sirturo Increased bedaquiline exposure Details Imatinib Bosutinib Bosulif Increased bosutinib exposure Details Imatinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Imatinib Brigatinib Alunbrig Increased brigatinib exposure Details Imatinib Budesonide Entocort Increased budesonide exposure Details Imatinib Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Imatinib Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Imatinib Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Cobimetinib Cotellic Increased cobimetinib plasma concentrations Details Imatinib Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Imatinib Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Imatinib Dabigatran Pradaxa® Increased dabigatran etexilate exposure Details Imatinib Dabigatran Etexilate Increased dabigatran etexilate exposure Details Imatinib Dasatinib Phyrago Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Imatinib Dexamethasone Injection Decadron Reduced imatinib exposure Details Imatinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced imatinib exposure Details Imatinib Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Imatinib Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Imatinib Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Dofetilide Tikosyn Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Imatinib Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details